Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AF28996 placebo-controlled trial in adults with Parkinson's disease and motor fluctuations
2025-524655-30-00Phase 2Authorised
- Sponsor
- Lundbeck
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Lu AF28996 with Placebo (2 arms). Primary endpoint: Change from baseline to Week 19 in daily good ON time based on Hauser diary entries. Planned start Oct 2026; status: authorised.
02
Drugs
Lu AF28996
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2025-524655-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524655-30-00.